Department of Health Sciences, University of York, UK.
BMC Med. 2011 Jul 21;9:89. doi: 10.1186/1741-7015-9-89.
The participant information sheet (PIS) provided to potential trial participants is a critical part of the process of valid consent. However, there is long-standing concern that these lengthy and complex documents are not fit-for-purpose. This has been supported recently through the application of a performance-based approach to testing and improving readability called user testing. This method is now widely used to improve patient medicine leaflets--determining whether people can find and understand key facts. This study applied for the first time a controlled design to determine whether a PIS developed through user testing had improved readability over the original, using a sheet from a UK trial in acute myeloid leukemia (AML16).
In the first phase the performance of the original PIS was tested on people in the target group for the trial. There were three rounds of testing including 50 people in total--with the information revised according to its performance after each of the first 2 rounds. In the second phase, the revised PIS was compared with the original in a parallel groups randomised controlled trial (RCT) A total of 123 participants were recruited and randomly allocated to read one version of the PIS to find and show understanding of 21 key facts.
The first, developmental phase produced a revised PIS significantly altered in its wording and layout. In the second, trial phase 66% of participants who read the revised PIS were able to show understanding of all aspects of the trial, compared with 15% of those reading the original version (Odds Ratio 11.2; Chi-square = 31.5 p < .001). When asked to state a preference, 87.1% participants chose the revised PIS (Sign test p < .001).
The original PIS for the AML16 trial may not have enabled valid consent. Combining performance-based user testing with expertise in writing for patients and information design led to a significantly improved and preferred information sheet. User testing is an efficient method for indicating strengths and weaknesses in trial information, and Research Ethics Committees and Institutional Review Boards should consider requesting such testing, to ensure that PIS are fit-for-purpose.
提供给潜在试验参与者的知情同意书(PIS)是有效同意过程的关键部分。然而,长期以来,人们一直担心这些冗长且复杂的文件不适合使用。最近,通过应用一种名为用户测试的基于性能的方法来测试和提高可读性,这种担忧得到了支持。这种方法现在被广泛用于改善患者用药说明书——确定人们是否能够找到和理解关键事实。本研究首次应用对照设计,使用来自英国急性髓细胞白血病(AML16)试验的知情同意书,确定通过用户测试开发的 PIS 是否比原始 PIS 更具可读性。
在第一阶段,对试验目标人群中的人测试原始 PIS 的性能。共进行了三轮测试,总共有 50 人参加——根据前两轮的表现对信息进行了修订。在第二阶段,在平行组随机对照试验(RCT)中比较修订后的 PIS 与原始 PIS。共招募了 123 名参与者,并随机分配阅读一份 PIS,以查找并展示对 21 个关键事实的理解。
第一阶段,开发阶段产生了一份在措辞和布局上有明显改变的修订后的 PIS。在第二阶段,试验阶段,阅读修订后的 PIS 的参与者中有 66%能够理解试验的所有方面,而阅读原始版本的参与者只有 15%(优势比 11.2;卡方=31.5,p<.001)。当被要求表示偏好时,87.1%的参与者选择修订后的 PIS(符号检验,p<.001)。
AML16 试验的原始 PIS 可能无法实现有效同意。将基于性能的用户测试与患者写作和信息设计方面的专业知识相结合,产生了一份显著改进且更受欢迎的信息表。用户测试是一种有效的方法,可以指出试验信息的优缺点,研究伦理委员会和机构审查委员会应考虑要求进行此类测试,以确保 PIS 适合使用。